24.5 C
New York
Thursday, July 3, 2025

Tag: Plug and Play

Plug and Play Launches Taiwan Office and Opens Applications for Inaugural Accelerator

TAOYUAN, June 25, 2025 /PRNewswire/ -- Plug and Play, the world's largest innovation platform, has officially opened its first office in Taoyuan City. This expansion...

Blockticity Launches Avalanche-Powered L1 to Authenticate $1.2B+ in Global Trade

MIAMI, June 12, 2025 /PRNewswire/ -- Blockticity, a blockchain and AI platform securing global trade documents, has launched a custom Avalanche Layer 1 network via...

AstriVax Therapeutics Further Strengthens Team with the Appointment of Dieter Weinand as New Chair of the Board of Directors

Leuven, Belgium, June 12, 2025AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the appointment of Dieter Weinand as Chair of the Board of Directors, effective June 12, 2025. Mr. Weinand is the former Chief Executive Officer of Bayer Pharma AG with more than 25 years of experience as a senior business leader in the pharmaceutical industry. He takes over from Dr. Jeanne Bolger, who served as Chair since 2022 and will remain on the Board as a non-executive independent director.

Plug and Play launches foundation and innovation lab to nurture the next generation of startup talent

New charitable foundation and hands-on robotics, software, and STEM lab to operate from Plug and Play Foundation's Innovation Lab, offering immersive learning and industry...

Multiple Farm Credit associations collaborate with Plug and Play to advance agricultural finance through new Seed4Growth Program

SUNNYVALE, Calif., June 9, 2025 /PRNewswire/ -- In a significant step forward for agricultural finance, American AgCredit (AAC), Farm Credit Services of America (FCSAmerica), Frontier...

Collaboration entre OBI Pharma et TegMine Therapeutics autour des ADC, reposant sur les technologies habilitantes GlycOBI® et TegMiner™

TAIPEI, Taïwan, 06 juin 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), une société internationale d’oncologie au stade clinique, spécialisée dans le développement de nouvelles thérapies contre le cancer, telles que les conjugués anticorps-médicaments (ADC) (4174. TWO), et TegMine Therapeutics, Inc. (TegMine), une entreprise biopharmaceutique américaine spécialisée dans le développement d’anticorps de premier ordre ciblant les glycanes et glycoprotéines tumoraux, ont conclu un accord-cadre de services (MSA) portant sur les ADC.

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related Master Services Agreement (MSA).

Plug and Play Expands Semiconductor Ecosystem Program with New Synopsys Collaboration to Accelerate Chip Design Innovation

SUNNYVALE, Calif., June 5, 2025 /PRNewswire/ -- Plug and Play, the world's largest innovation platform based in Silicon Valley, has announced a new collaboration with...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPlug and Play